Publication details

Léčba dyslipidemie u pacientů s metabolickým syndromem

Title in English Dyslipidemia and metabolic syndrom
Authors

SOŠKA Vladimír

Year of publication 2015
Type Article in Periodical
Magazine / Source Interní medicína pro praxi
MU Faculty or unit

Faculty of Medicine

Citation
Field Biochemistry
Keywords dyslipidemia; metabolic syndrom; HDL cholestor; triglycerides; statins; fenofibrate
Description Dyslipidemia is one of the main components of the metabolic syndrom. Is is characterized by elevated triglycerides, low HDL-cholesterol and elevated concentrations of small aterogenic LDL particles. The basic step in treatment should be always a lifestyle changes, especially changes in diet, weight optimization and ban of smoking. Pharmacotherapy DLP is indicated if a patient is in very high or high risk of fatal cardiovascular event during next 10 years and if (at the same time) is LDL-cholesterol higher than its target level. Pharmacotherapy is based on statins therapy, in case of their intolerance ezetimibe. If target level of LDL-cholesterol is achieved and persist elevated levels of triglycerides and/or decreased HDL-cholesterol, adding fenofibrate to a statin should be considered.

You are running an old browser version. We recommend updating your browser to its latest version.

More info